UTRF licenses cell line commercial rights to CytoSen Therapeutics

UTRF NewThe University of Tennessee’s Research Foundation recently executed a license granting CytoSen Therapeutics Inc.  the commercial rights to use the K-562 cell lines to produce an innovative natural killer cell therapy that harnesses the power of a person’s own immune cells to help fight cancer. Read more here.

Stay connected with us on Twitter and LinkedIn. Article ideas and other suggestions should be sent to Include the name and contact information (phone and email) for follow-up.